Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immatics NV
(NQ:
IMTX
)
11.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immatics NV
Immatics Announces Second Quarter 2024 Financial Results and Business Update
August 13, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
July 31, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
July 18, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
March 21, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Pricing of $175 Million Public Offering
January 17, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Proposed Public Offering
January 17, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
November 08, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
October 24, 2023
From
https://immatics.com/
Via
GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023
Via
ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 17, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
August 10, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
July 24, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 16, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
May 02, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
May 01, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Full Year 2022 Financial Results and Corporate Update
March 21, 2023
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Third Quarter 2022 Financial Results and Business Update
November 17, 2022
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
October 10, 2022
From
https://immatics.com/
Via
GlobeNewswire
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
October 10, 2022
From
https://immatics.com/
Via
GlobeNewswire
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 02, 2022
From
Bristol Myers Squibb
Via
Business Wire
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
December 14, 2021
From
Bristol Myers Squibb
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.